C型肝炎ウイルス感染患者を対象としたSB-497115-GRの日本における第II相臨床試験

基本情報

NCT ID

NCT01636778

ステータス

完了

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

45

治験依頼者名

GlaxoSmithKline

概要

The purpose of this study is to assess the ability of SB-497115-GR to raise platelet counts in thrombocytopenic patients with hepatitis C virus (HCV) infection (platelet count \<80,000 /μL, suggestive of compensated cirrhosis) to a level desirable to initiate antiviral therapy and to assess the ability of SB-497115-GR to maintain platelet counts at a level sufficient to minimise dose reductions of pegylated interferon (Peg-IFN) and ribavirin (RBV) therapy with the expectation that a lower rate of Peg-IFN dose reduction and omission will translate to a higher rate of sustained viral response.

対象疾患

介入

依頼者（Sponsor）